2. TGF-beta/Smad
  3. TGF-β Receptor
  4. Unasnemab

Unasnemab  (Synonyms: MT-3921; rH116A3)

Cat. No.: HY-P99959 Purity: 99.00%
COA
SDS
Technical Support

Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments.

For research use only. We do not sell to patients.

CAS No. : 2379805-59-9

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Unasnemab Featured Recommendations:

Unasnemab Related Antibodies

Top Publications Citing Use of Products

View All TGF-β Receptor Isoform Specific Products:

View All Isoforms
ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 TGFβR2 ACVR2A ACVR2B

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments[1][2][3].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

RGMA
In Vitro

Unasnemab (48 h) significantly alleviated the reduction in average neurite length of NB-1 human neuronal cells cocultured with Tax-expressing JPX9 cells (a Tax-inducible cell line) in a dose-dependent manner[1].
Unasnemab (0.001-10 μg/mL, 72 h) significantly reversed the increased concentration of neurofilament light chain (NF-L) in the culture medium of NB-1 cells cocultured with PBMCs with HTLV-1-associated myelopathy (HAM) in a dose-dependent manner[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Unasnemab Related Antibodies
In Vivo

Unasnemab (30 mg/kg, i.v., once weekly, 6 weeks) exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice and Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic mice[2].
Unasnemab (10 mg/kg, i.p., twice weekly, starting 3 days post-surgery for a total of 9 injections) significantly ameliorates bilateral common carotid artery stenosis (BCAS)-induced pathological changes and cognitive deficits in mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 6-week-old db/db mice (type 2 diabetes model) and STZ-induced type 1 diabetic 8-week-old C57BL/6JJmsSlc mice[2]
Dosage: 30 mg/kg
Administration: i.v., once weekly, 6 weeks
Result: Increased the number and density of DCX-positive immature neurons in the hippocampal granular cell layer (GCL), and improved their morphological defects.
Significantly increased the Discrimination Index (DI) in both Novel Object Recognition Test (NORT) and Object Placement Test (OPT) to restore hippocampus-dependent memory.
Showed no significant effects on STZ-induced body weight loss and blood glucose elevation.
Animal Model: Adult male C57BL/6J mice (8-10 weeks old) were used to establish the vascular dementia (VaD) model via bilateral common carotid artery stenosis (BCAS)[3]
Dosage: 10 mg/kg
Administration: i.p., twice weekly, starting 3 days post-surgery for a total of 9 injections
Result: Reversed the reduction of doublecortin (DCX)-positive immature neurons in the hippocampal granular cell layer (GCL) and subgranular zone (SGZ).
Decreased the number of cleaved caspase-3/DCX double-positive apoptotic cells.
Promoted the survival and maturation of newborn neurons.
Attenuated the loss of cholinergic innervation in the hippocampal dentate gyrus.
Improved cognitive function.
Did not affect cerebral blood flow (CBF) in BCAS mice.
Clinical Trial
Gene ID

56963  [NCBI]

Accession

Q96B86-1
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

144.88 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Unasnemab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Loaded Unasnemab on AHC2 biosensor, can bind RGMA Protein, Human (HEK293, His, HY-P76572) with an affinity constant of 1.418E-08 M as determined in BLI assay.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Unasnemab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Unasnemab2379805-59-9MT-3921 rH116A3MT3921MT 3921TGF-β ReceptorTransforming growth factor beta receptorsdiabetes-induced neurological impairmentsspinal cord injuryRGMaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Unasnemab
Cat. No.:
HY-P99959
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.